Compass Pathways

Compass Pathways is a British biopharmaceutical company focused on developing psychedelic compounds and related therapeutic models for serious mental-health conditions. Its principal program is COMP360, a proprietary formulation of synthetic psilocybin being studied in combination with psychological support. The company has concentrated particularly on treatment-resistant depression, a condition in which patients do not achieve adequate improvement from commonly used antidepressant treatments. The organization originated as a nonprofit initiative before changing into a for-profit company in 2016. Its formation was associated with George Goldsmith and Ekaterina Malievskaia, who sought to advance a medically supervised approach to psychedelic treatment. The company attracted backing from technology and biotechnology investors, including Peter Thiel, while Christian Angermayer has been described as an important figure in its early financing and development. Compass has subsequently built a research network involving academic psychedelic scientists and investigators working on pharmacology, clinical development, and novel psychoactive compounds. COMP360 is designed to be administered in a controlled clinical environment alongside psychological support rather than as a conventional take-home antidepressant. The company’s development model therefore involves both the drug candidate and an intended treatment infrastructure, including preparation, supervised dosing, and integration. This approach reflects the practical and regulatory challenges of translating psychedelic research into a scalable medical service. The program has received Breakthrough Therapy designation from the United States Food and Drug Administration for treatment-resistant depression, a designation intended to facilitate development and regulatory review for therapies addressing serious conditions with preliminary evidence of meaningful benefit. Compass became the first psychedelic-medicine company to list on the Nasdaq, in 2020, and has been described as one of the largest and most advanced businesses in the emerging psychedelic pharmaceutical sector. Its clinical work progressed from early-stage studies into larger controlled trials. The company has reported positive findings from late-stage development, including improvement on the Montgomery–Åsberg Depression Rating Scale, or MADRS, among participants with treatment-resistant depression. Regulatory approval has not been established merely by the existence of these results, and COMP360 remains an investigational therapy unless and until applicable regulators authorize it. The company’s activities extend beyond COMP360. It has entered relationships with independent researchers, including scientists associated with the study of psychedelic pharmacology and novel compounds. These collaborations indicate an effort to create a broader pipeline rather than rely permanently on a single psilocybin product. At the same time, Compass has drawn criticism over its patent strategy, including efforts relating to psychedelic formulations, treatment methods, and certain mushroom species. Supporters view intellectual-property protection as necessary to attract investment into expensive clinical development; critics argue that broad or foundational patents could restrict research access and privatize knowledge associated with naturally occurring psychedelics. In October 2024, following the United States Food and Drug Administration’s rejection of Lykos Therapeutics’ application for MDMA-assisted therapy for post-traumatic stress disorder, Compass announced a workforce reduction of approximately 30 percent and a narrower research focus. The move illustrated the financial and regulatory pressure facing psychedelic drug developers. Compass remains an active public biotechnology company whose principal strategic challenge is to demonstrate that psychedelic treatment can produce reliable, durable, and clinically manageable bene…

Compass Pathways emerged from a nonprofit effort to investigate psychedelic-assisted treatment as a possible response to serious mental-health conditions. The organization changed from nonprofit status to a for-profit company in 2016, with George Goldsmith and Ekaterina Malievskaia associated with its founding. Its early development was supported by investors from technology and biotechnology circles, including Peter Thiel. Christian Angermayer has also been identified as an important early supporter of the company. The company’s strategy centered on developing a pharmaceutical-grade psilocybin product and a reproducible system for delivering it in a supervised clinical setting. Its lead candidate, COMP360, is a synthetic psilocybin formulation intended to be used with psychological support. Unlike standard oral antidepressants, the proposed treatment model involves preparation before dosing, monitoring during the psychedelic session, and follow-up support. This means that Compass has had to address not only pharmacology and clinical efficacy, but also therapist training, clinic operations, patient selection, safety monitoring, and the regulatory requirements associated with an altered state of consciousness. Compass advanced COMP360 through clinical studies in treatment-resistant depression, a difficult-to-treat condition affecting patients who have not responded adequately to existing therapies. The program received Breakthrough Therapy designation from the United States Food and Drug Administration, reflecting preliminary evidence and the seriousness of the target condition. Subsequent controlled studies and later-stage development generated evidence of improvement measured using the Montgomery–Åsberg Depression Rating Scale. The company has described phase 3 results as demonstrating clear benefit for participants, although the product remains an investigational therapy pending regulatory review and authorization. The company became a notable institutional and financial marker for the psychedelic-medicine field when it listed on Nasdaq in 2020 under the ticker CMPS. The listing made Compass the first psychedelic-medicine company to trade on Nasdaq and helped give the emerging sector greater visibility among public-market investors. It also subjected the company to the financial, clinical, and regulatory expectations that apply to publicly traded biotechnology businesses. Beyond COMP360, Compass has worked with independent academic scientists on the discovery and development of potential psychedelic medicines. Researchers associated with these efforts include Jason Wallach, Hamilton Morris, and Adam Halberstadt. One associated research program was reported to have pursued patents covering more than 200 novel compounds by May 2024. These relationships reflect the company’s interest in building a longer-term pipeline of compounds rather than depending exclusively on psilocybin. Intellectual property has been a recurring point of controversy. Compass has faced criticism for patenting or seeking patents covering psychedelic drugs, treatment methods, and aspects of naturally occurring psilocybin mushrooms. Critics contend that broad protection could limit scientific inquiry or give a private company control over discoveries connected with traditional or naturally occurring substances. The company’s position is consistent with the conventional biotechnology model in which patents are used to protect investment in research, clinical trials, manufacturing, and regulatory approval. The dispute illustrates the tension between open scientific access to psychedelic knowledge and the commercial incentives required to develop a regulated medicine. In October 2024, Compass responded to a difficult environment for psychedelic drug developers by announcing a workforce reduction of approximately 30 percent and a narrower research strategy. The decision followed the FDA’s rejection of Lykos Therapeutics’ MDMA application for post-traumatic stress disorder. That event heightened scrutiny of psychedelic clinical evidence, trial design, treatment infrastructure, and regulatory standards. Compass continued to focus on COMP360 and its most strategically relevant research programs. Its current identity is therefore that of a public biotechnology company attempting to convert promising but operationally complex psychedelic science into an approved, scalable treatment for serious depression.

1. 2024Research refocusing and workforce reduction

   Compass announced a roughly 30 percent workforce reduction and a narrower research focus amid heightened regulatory and sector pressure.

   Source
2. 2020Nasdaq listing

   Compass became the first psychedelic-medicine company to list on Nasdaq, trading under the symbol CMPS.

   Source
3. 2016Conversion from nonprofit initiative to for-profit company

   Compass changed from a nonprofit organization into a for-profit pharmaceutical company and began building a commercial development program around psychedelic medicines.

   Source
4. FDA Breakthrough Therapy designation for COMP360

   The FDA granted Breakthrough Therapy designation to COMP360 for treatment-resistant depression.

   Source
5. Late-stage development of COMP360

   COMP360 progressed through phase 3 testing, with reported benefit measured by the MADRS depression-rating scale.

   Source

Innovative, clinically supervised psychedelic therapies for serious mental-health conditions

• COMP360Investigational synthetic psilocybin therapy

  COMP360 is Compass Pathways’ principal investigational medicine. It is a proprietary formulation of synthetic psilocybin being developed for administration in a controlled clinical setting together with psychological support. The program has primarily targeted treatment-resistant depression, combining the drug session with preparation, supervision, and follow-up rather than treating psilocybin as a conventional unsupervised prescription. COMP360 has received FDA Breakthrough Therapy designation and has advanced into phase 3 testing, but it is not an approved commercial medicine unless and until regulators grant authorization.

• 2024Narrow the research portfolio and reduce staffStrategy

  The FDA’s rejection of Lykos Therapeutics’ MDMA application increased attention on the evidentiary and regulatory risks facing psychedelic drug developers.

  What changed. Compass announced a workforce reduction of approximately 30 percent and a narrower research focus.

  Aftermath. The decision concentrated resources on the company’s most advanced and strategically important programs while signaling a more cautious approach to pipeline expansion.

  Source
• 2020List on NasdaqOther

  Compass sought access to public capital and visibility while psychedelic medicines were becoming a distinct biotechnology investment category.

  What changed. The company completed a Nasdaq listing under the ticker CMPS.

  Aftermath. Compass became the first psychedelic-medicine company listed on Nasdaq and one of the sector’s most visible public companies.

  Source
• 2016Adopt a for-profit pharmaceutical-development modelStrategy

  The organization began as a nonprofit initiative but required a commercial structure to support drug discovery, clinical trials, manufacturing, and regulatory development.

  What changed. Compass converted into a for-profit company and pursued development of psychedelic medicines, led by the COMP360 program.

  Aftermath. The change enabled substantial private investment and ultimately supported the company’s public listing and late-stage clinical development.

  Source

• Controversy over psychedelic patentsControversy

  Compass has been criticized for pursuing patents involving psychedelic compounds, treatment approaches, and certain psilocybin mushroom species. The controversy concerns whether broad intellectual-property rights could restrict research or privatize knowledge associated with naturally occurring psychedelics.

  Source

• 2024Compass narrows research focus and reduces workforce

  After the FDA rejected Lykos Therapeutics’ MDMA application for post-traumatic stress disorder, Compass announced that it would reduce its workforce by about 30 percent and concentrate its research activities more narrowly.

  Leadership changeOther
  Source
• 2020Compass Pathways becomes the first psychedelic-medicine company listed on Nasdaq

  Compass Pathways completed a public listing on Nasdaq under the ticker CMPS, giving the developing psychedelic-medicine sector a prominent publicly traded company.

  Other
  Source
• COMP360 receives FDA Breakthrough Therapy designation

  The company’s psilocybin program for treatment-resistant depression received Breakthrough Therapy designation from the United States Food and Drug Administration.

  Regulation
  Source
• Compass reports late-stage clinical benefit for COMP360 in treatment-resistant depression

  Compass reported that phase 3 testing showed a measurable benefit for participants with treatment-resistant depression using the MADRS depression-rating scale.

  Product generationRegulation
  Source

1. Compass Pathways
2. Compass Pathways official website